Related Experiment Video
Updated: Jan 7, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Unlocking New Horizons: Antibody-Drug Conjugates in Small Cell Lung Cancer
Jiayu Liu1, Yan Cui1, Dongying Liao2
1School of Basic Medicine, Changchun University of Chinese Medicine, Changchun 130117, China.
Abstract:
Antibody-drug conjugates (ADCs), an emerging class of antitumor agents, have revolutionised the therapeutic landscape in oncology by integrating the cytotoxic efficacy of chemotherapy with the precision of targeted therapy. These agents have also demonstrated considerable potential in the treatment of small cell lung cancer (SCLC). Numerous clinical trials evaluating ADCs in SCLC are currently underway. Although encouraging outcomes have been observed, several challenges persist, including drug resistance, treatment-related toxicities, and the identification of suitable biomarkers for patient selection. A comprehensive understanding of the mechanisms underlying ADCs, along with a systematic review of their clinical development in SCLC, may provide valuable insights and strategies to address these issues. In this review, we elucidate the structure and mechanisms of action of ADCs, summarise key clinical trials in SCLC, discuss existing challenges, and suggest future directions to facilitate the advancement and clinical application of ADC-based therapies for SCLC.
Insights
Antibody-drug conjugates (ADCs) show promise for small cell lung cancer (SCLC) treatment by combining targeted therapy and chemotherapy. Further research is needed to overcome challenges like drug resistance and toxicity for effective ADC application in SCLC.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Antibody-drug conjugates (ADCs) represent a significant advancement in cancer therapy.
- ADCs merge targeted delivery with potent cytotoxic agents for enhanced antitumor efficacy.
- Their application in small cell lung cancer (SCLC) is an area of active clinical investigation.
Purpose of the Study:
- To review the structure, mechanism of action, and clinical development of ADCs in SCLC.
- To summarize current clinical trials and outcomes of ADCs for SCLC treatment.
- To identify and discuss challenges and future directions for ADC-based therapies in SCLC.
Main Methods:
- Systematic review of existing literature on ADCs in oncology.
- Analysis of clinical trial data for ADCs in small cell lung cancer.
- Elucidation of ADC mechanisms and discussion of therapeutic challenges.
Main Results:
- ADCs have demonstrated potential in treating SCLC, with several clinical trials ongoing.
- Encouraging outcomes have been observed, but challenges remain.
- Key issues include the development of drug resistance, treatment-related toxicities, and the need for predictive biomarkers.
Conclusions:
- ADCs offer a promising therapeutic strategy for small cell lung cancer.
- Addressing challenges such as resistance, toxicity, and patient selection is crucial for optimizing ADC therapy.
- Further research and systematic reviews are essential to advance the clinical application of ADCs in SCLC.
More Related Videos
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...